The Prediction of Type 1 Diabetes Development and Diagnosis of Its Asymptomatic Phase Using Autoantibodies to Human Islets of Langerhans Long Before the Onset of the Disease
The article deals with an analysis of the latest data of world literature and the results of own twenty-year researches on studying antibodies to human islets of Langerhans, and their use as a test for predicting the risk of type 1 diabetes mellitus (DM), and diagnosis of asymptomatic phase of its development in normoglycemic children of Ukraine. The majority of foreign diabetologists adhere to the same opinion that the determination of islet autoantibodies (IAA) of ICA, IAA, GADA, IA‑2A and ZnT8 in human blood serum has the high diagnostic value and specificity for detecting the autoimmune destructive process in islets, starting with the very early asymptomatic phase of DM development, long before (sometimes months or years before) the manifestation of clinical symptoms of the disease in normoglycemic person. In the simultaneous detection of positivity to the majority of IAA, the development of type 1 DM is inevitable. Our observations, performed for the first time with the participation of children of Ukraine, fully confirm this conclusion. The accuracy of predicting the risk of DM is directly related to the number of different types of IAA, which are used simultaneously, — the more of them, the higher the accuracy of the prediction, and also it is associated with HLA-DR-DQ genotype, the age of the examined person, autoantibodies titer, and the time that has elapsed after the first positive test. With the simultaneous screening of four to five IAA, the accuracy of DM prediction exceeds 90 %. A characteristic feature of IAA is the variability of their titer in the blood, i.e. its increase is alternated with reversion to a normal level. At the same time, IAA are used to detect remaining residual beta cells in the pancreas late after insulin therapy that is necessary for the assignment of more effective immunologic intervention, as well as for more precise differentiation between type 1 and type 2 DM in adults.
Full Text:PDF (Русский)
Reference books of basic performance indivators of endocrinology care of Ukraine indicators. Кyiv, 2001-2015 rr. (Ukrainian)
Zak КP, Popova VV. Immune intervention in therapy of diabetes mellitus (state-of-the-art review). Diabet, ozhyrinnia, metabolicheskiy sindrom. 2015;6(4):31–44. (Russian)
Zak КP, Тron’ko MD, Popova VV, Butenko AK. Diabetes mellitus. Immunity. Cytokines. К.: Кniga plus, 2015;485 s. (Russian)
Popova VV. Leucocytes storage and immune phenotype of peripheral blood lymphocytes in DAAt-positive and DAAt-negative about content of diabetes associated autoantibodies in children with preclinical and early clinical stage of type 1 diabetes mellitus. Zdorovia dytyny. 2015;2(61):45-51. (Ukrainian)
Popova VV. Products of diabetes associated autoantibodies to the isles autoantigens (IA-2a, GADA, IAA) in children and teenagers on the stages of evolution of type 1 diabetes mellitus 1 as basis of clinical and immunological algorithm of preclinical diagnostics of disease. Sovremennaya pediatriya. 2015;2(66):113-118. (Ukrainian)
Popova VV. Content of diabetes associated autoantibodies to the islet autoantigens (IA-2a, GADA, IAA) and level of different types of cytokines in children and teenagers on preclinical and early clinical stages of development of type 1 diabetes mellitus. International Journal of Endocrinology. 2015;2(66):138-146. (Russian)
Popova VV. Frequency of type 1 diabetes mellitus and immunological monitoring in normoglycemic healthy children with the burdened heredity and positive in relation to diabetes associated autoantibodies to the Langerhans islets. Endokrinologia. 2008;13(2):211–219. (Ukrainian)
Popova VV, Zak KP. Opening of autoantibodies to the Langerhans islets is the distinguished achievement in area of prediction of diagnostics of type 1 diabetes mellitus (Review with including of own data). Likarska sprava. 2006;7:3–12. (Ukrainian)
Popova VV, Zak KP. Chemokines in men with type 1 diabetes mellitus. Ukr. medychmyi chasopys. 2008;67(5):1–14. (Ukrainian)
Popova VV, Man’kovskyi BN. Determination of frequency of antibodies to thyrosinphosphatase (IA-2a) as immunological strategy of the early preclinical stage of type 1 diabetes mellitus in children and teenagers. Zdorovie zhenshchyny. 2002;3:34–41. (Russian)
Tron’ko ND, Popova VV, Zak KP, Man’kovskyi BN. About the research prospective program "Immunity in preclinical period of type 1 diabetes mellitus development", created in SI "Institute of Endocrinology and Metabolism named after VP. Komisarenko of Ukrainian NAMS". Еndokrynologia. 2010;15(2):180–191. (Ukrainian)
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;38(9911):69–82.
Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes – considerations for attempts to prevent and reverse the disease. Diabetes Care. 2015;38(6):979–988.
Bingley PJ. Clinical application of diabetes antibody testing. J. Clin. Endocrinol. Metab. 2010;95(1):25–33.
Bingley PJ, Boulware DC, Krischer JP. Type 1 Diabetes TrialNet Study Group. The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia. 2016;59(3):542–549.
Bluestone JA, Herold K. Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293–1300.
Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care. 2015;38(6):989–996.
Bonifacio E, Hummel M, Walter M. et al. IDDM and multiple family history of type 1 diabetes combined to identify neonates at high risk for type 1 diabetes. Diabetes Care. 2004;27(11):2695–2700.
Bonifacio E., Ziegler AG, Klingensmith G. et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015;313(15):1541–1549.
Bottazzo GF, Florin-Christensen A, Doniach D. Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974;2(7892):1279–1283.
Christie MR, Hollands JA, Brown TJ. et al. Detection of pancreatic islet 64,000 M (r) autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylase. J. Clin. Invest. 1993;92(1):240–248.
Decochez K, Truyen J, Van der Anwera B. et al. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk type 1 diabetes. Diabetologia. 2005;48(4):687–694.
Drexhage HA, Dik WA, Leenen PJ, Versnel MA. The Immune pathogenesis of type 1 diabetes: not only thinking outside the cell but also outside the islet and out of the box. Diabetes. 2016;65(8):2130–2133.
Eisenbarth GS, Jeffrey J. The natural history of type 1A diabetes. Arq. Bras. Endocrinol. Metabol. 2008;52(2):146–155.
Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 2008;29(1):42–61.
Endesfelder D, Hagen M, Winkler C. et al. A novel approach for the analysis of longitudinal profiles reveals delayed progression to type 1 diabetes in a subgroup of multiple-islet-autoantibody-positive children. Diabetologia. 2016;59(10):2172–2180.
Fourlanos S, Dotta F, Greenbaum CJ. et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48(11):2206–2212.
Hawa MI, Kolb H, Schloot N. et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype. Diabetes Care. 2013;36:908–913.
IDF Diabetes Atlas, Seventh edition. 2016.
Insel RA, Dunne JL, Atkinson MA. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–1974.
Knip M. Prediction and prevention of type 1 diabetes. Acta Pediatr. 1998;425:54–62.
Krischer JP, Lynch KF, Schatz DA. et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015;58(5):980–987.
Lampasona V, Petrone A, Tiberti C. et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care. 2010;33(1):104–108.
Larsson EH, Vehik K, Haller MJ. et al. Growth and risk for islet autoimmunity and progression to type 1 diabetes in early childhood: the environmental determinants of diabetes in the Young Study. Diabetes. 2016;65(7):1988–1995.
Lebastchi J, Herold KC. Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harb. Perspect. Med. 2012;2(6): doi: 10.1101/cshperspect.a007708.
Leslie RDG, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in type 1 (insulin-dependent) diabetes. Diabetologia. 1999;42(1):3–14.
Miao D, Guyer MK, Dong F. et al. GAD65 Autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes. 2013;62:4174–4178.
Parikka V, Nanto-Salonen K, Saarinen M. et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia. 2012;55(7):1926–1936.
Patterson CC, Dahlquist GG, Gyürüs E. et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-2020: a multicentre prospective registration study. Lancet. 2009;373(9680):2027–2033.
Phelps EA, Cianciaruso C, Michael IP. et al. Aberrant accumulation of the diabetes autoantigen GAD65 in Golgi membranes in conditions of ER stress and autoimmunity. Diabetes. 2016;65(9):2686–2699.
Pietropaolo M, Yu S, Libman IM. et al. Cytoplasmic islet cell antibodies remain valuable in defining risk or progression to type 1 diabetes in subjects with other islet autoantibodies. Pediatr. Diabetes. 2005;6(4):184–192.
Raab J, Haupt F, Scholz M. et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6(5):e011144.
Rabin DU, Pleasic SM, Shapiro JA. et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J. Immunol. 1994;152:3183–3187.
Röep BO, Atkinson M. Animal model have little to teach us about type 1 diabetes. In support of this proposal. Diabetologia. 2004;47(10):1650–1656.
Rolandsson O, Hampe ChS, Wennberg P. et al. Prevalence and regional distribution of sutoantibodies against GAD65Ab in a European population without diabetes: The EPIC-InterAct Study. Diabetes Care. 2015;38(8):114–115.
Schlosser M, Lampasona V, Williams AJK. et al. Combined appearance of autoantibodies against GAD, IA-2, insulin and ZnT8 in the islet autoantibody standardization program 2013 proficiency workshop. Diabetologia. 2014;57(1):334.
Schlosser M, Mueller PW, Lampasona V. et al. Combined measurement of autoantibodies against GAD, IA-2, insulin and ZnT8 in the Diabetes Autoantibody Standardization Program 2009 Workshop. Diabetologia. 2010;53(1):178.
Törn C, Mueller PW, Schlosser M. et al. Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia. 2008;51:846–852.
Vehik K, Lynch KF, Schatz DA. et al. Reversion of b-cell autoimmunity changes risk of type 1 diabetes: TEDDY Study. Diabetes Care. 2016;39(9):1535–1542.
Vermeulen I, Weets I, Costa O. et al. Seroconversion to persistent antibody-positivity occurs frequently after age 10 and is best predicted by CAD antibodies. Diabetologia. 2010;53(1):180.
Wenzlau JM, Frisch LM, Gardner TJ. et al. Novel antigens in type 1 diabetes: the importance of ZnT8. Current Diabetes Reports. 2009;9:105–112.
Wenzlau JM, Gardner TJ, Yu L. et al. Composite multi-antigen probes enhances detection of type 1 diabetes autoantibodies. Diabetologia. 2009;52(Suppl. 1):266.
Wenzlau JM, Juhl K, Yu L. et al. The cation efflux transporter ZnT8 (Slc 30 A8) is a major antiantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. USA. 2007;104:17040–17045.
Williams AJ, Lampasona V, Schlosser M. et al. Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes. Diabetes. 2015;64(9):3239–3246.
Williams AJ, Lampasona V, Wyatt R. et al. Reactivity to N-terminally truncated GAD65(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes. Diabetes. 2015;64(9):3247–3252.
Xu P, Krischer JP; Type 1 Diabetes TrialNet Study Group. Prognostic classification factors associated with development of multiple autoantibodies, dysglycemia, and type 1 diabetes – a recursive partitioning analysis. Diabetes Care. 2016;39(6):1036–1044.
Yu L, Dong F, Miao D. et al. Proinsulin/insulin autoantibodies measured with electrochimiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care. 2013;36:2266–2270.
Ziegler AG, Bonifacio E, and BABYDIAB–BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012;55(7):1937–1943.
Ziegler AG, Danne T, Dunger DB. et al. Primary prevention of beta-cell autoimmunity and type 1 diabetes – The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives. Mol. Metab. 2016;5(4):255–262.
Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity. 2010;32(4):468–478.
Ziegler AG, Bonifacio E, Powers AC. et al. Type 1 diabetes prevention: a goal dependent on accepting a diagnosis of an asymptomatic disease. Diabetes. 2016:65(11):3233–3239.
Ziegler AG, Pflueger M, Winkler C. et al. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J. Autoimmun. 2011;37(1):3–7.
Ziegler AG, Rewers M, Simell O. et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473–2479.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2018